Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells

Details

• Personal Author:
  Campen MJ ; Drager LF ; Lorenzi-Filho G ; Pedrosa RP ; Polotsky VY ; Sanchez B ; Zychowski KE
• Description:
  Background and aims: Obstructive sleep apnea (OSA) is characterized by intermittent airway obstruction and systemic hypoxia during sleep, which can contribute to an increase in reactive oxygen species, vascular remodeling, vasoconstriction and ultimately cardiovascular disease. Continuous positive airway pressure (CPAP) is a clinical therapy that maintains airway patency and mitigates several symptoms of OSA. However, it is currently unknown whether CPAP therapy also reduces the overall inflammatory potential in the circulation; to address this in an unbiased manner, we applied a novel endothelial biosensor approach, the serum cumulative inflammatory potential (SCIP) assay. Methods: We studied healthy controls (n = 7), OSA subjects receiving no treatment, (OSA controls) (n = 7) and OSA subjects receiving CPAP for 3 months (n = 8). Serum was obtained from OSA subjects before and after CPAP or no treatment. A battery of quantitative and functional assays was performed to assess the serum inflammatory potential, in terms of endothelial responses. For the SCIP assay, human coronary artery endothelial cells (hCAECs) were incubated with 5% serum in media from individual subjects for 4 h. qPCR was performed to assess endothelial inflammatory transcript (ICAM-1, VCAM-1, IL- 8, P-selectin, CCL5, and CXCL12) responses to serum. Additionally, transendothelial resistance was measured in serum-incubated hCAECs following leukocyte challenge. Results: hCAECs exhibited significant increases in VCAM-1, ICAM-1, IL-8 and P-selectin mRNA when incubated with serum from OSA patients compared to serum from healthy control subjects. Furthermore, compared to no treatment, serum from CPAP-treated individuals was less potent at inducing inflammatory gene expression in the SCIP assay. Similarly, in a leukocyte adhesion assay, naïve cells treated with serum from patients who received CPAP exhibited improved endothelial barrier function than cells treated with OSA control serum. Conclusions: OSA results in greater serum inflammatory potential, thereby driving endothelial activation and dysfunction. [Description provided by NIOSH]
• Subjects:
  Biological Assay Blood Cardiovascular Diseases Cardiovascular System Immune System Lung Lung Diseases Occupational Health Respiratory System Respiratory Tract Diseases Safety

  More +
• Keywords:
  Airway Obstruction Author Keywords: Obstructive Sleep Apnea Bioassay Bioassays Blood Serum Cardiovascular Disease Endothelial Cells Hypoxia Immune Reaction Inflammation Oxygen Deprivation Serum Sleep Apnea Vasoactive Agents

  More +
• ISSN:
  0021-9150
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Journal Article
• Place as Subject:
  Maryland ; New Mexico ; OSHA Region 3 ; OSHA Region 6
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  59-66
• Volume:
  254
• NIOSHTIC Number:
  nn:20049332
• Citation:
  Atherosclerosis 2016 Nov; 254:59-66
• Contact Point Address:
  Matthew J. Campen, MSC09 5360, University of New Mexico, Albuquerque, NM 87131, USA
• Email:
  mcampen@salud.unm.edu
• Federal Fiscal Year:
  2017
• NORA Priority Area:
  Manufacturing
• Performing Organization:
  University of New Mexico Health Sciences Center, Albuquerque, New Mexico
• Peer Reviewed:
  True
• Start Date:
  20150930
• Source Full Name:
  Atherosclerosis
• End Date:
  20190929
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:d495c8792de239a8524dfbbd8568fe2a74d37dd00f0ec0fbe900eb231ade5d39c605e618e47cf6ca94bc387592a11455bb562910bf3445dddc956f00072e4d25
• Download URL:
  https://stacks.cdc.gov/view/cdc/203803/cdc_203803_DS1.pdf
• File Type:
  [PDF - 1.07 MB ]